Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drug Metabolism And Disposition

• Publication date

  2016-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.115.068601PMID 26956641
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Variable Selection

  2019cited by this paper
• Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions Involving Inhibitory Metabolite: A Case Study of Amiodarone

  2015cited by this paper
• Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide

  2015cited by this paper
• A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development

  2013cited by this paper
• Pharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy

  2013cited by this paper
• Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology

  2012cited by this paper
• Prediction of Relative In Vivo Metabolite Exposure from In Vitro Data Using Two Model Drugs: Dextromethorphan and Omeprazole

  2012cited by this paper
• Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data

  2012cited by this paper
• Predicting clearance in humans from in vitro data.

  2011cited by this paper
• Regularization Paths for Generalized Linear Models via Coordinate Descent.

  2010cited by this paper
• Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

  2010influential reference
• Metabolism of 1′- and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7

  2010cited by this paper
• Inverse Modelling, Sensitivity and Monte Carlo Analysis in R Using Package FME

  2010cited by this paper
• Pharmacologically active metabolites of currently marketed drugs: potential resources for new drug discovery and development.

  2010cited by this paper
• Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

  2009cited by this paper
• Characterization of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein (IFABP): Potential Role of IFABP as an Alternative to Albumin for in Vitro-in Vivo Extrapolation of Drug Kinetic Parameters

  2009cited by this paper
• Predicting circulating human metabolites: how good are we?

  2009cited by this paper
• Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

  2008influential reference
• The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities

  2008cited by this paper
• Contribution of the N-Glucuronidation Pathway to the Overall in Vitro Metabolic Clearance of Midazolam in Humans

  2008cited by this paper
• Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450‐3A Activity: Comparison With Grapefruit Juice

  2007influential reference
• Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

  2007influential reference
• Prediction of intestinal first-pass drug metabolism.

  2007influential reference
• Comparison of midazolam and simvastatin as cytochrome P450 3A probes

  2006cited by this paper
• GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

  2006cited by this paper
• Metabolites and safety: What are the concerns, and how should we address them?

  2006cited by this paper
• Role of pharmacologically active metabolites in drug discovery and development.

  2006cited by this paper
• The pharmacokinetics of midazolam in man

  2004cited by this paper
• Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens

  2004cited by this paper
• Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.

  2004cited by this paper
• Validated assays for human cytochrome P450 activities.

  2004cited by this paper
• ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION

  2004cited by this paper
• Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity

  2004influential reference
• Cytochrome P450 3A expression and activity in the human small intestine

  2004cited by this paper
• Intravenous and oral alfentanil as in vivo probes for hepatic and first‐pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis

  2004influential reference
• Drug metabolites in safety testing.

  2003cited by this paper
• In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

  2003cited by this paper
• Drug metabolites in safety testing.

  2002cited by this paper
• Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

  2002cited by this paper
• In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.

  2002cited by this paper
• Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.

  2002cited by this paper
• Practical identifiability analysis of large environmental simulation models

  2001cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

  1999influential reference
• Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem

  1998influential reference
• The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin

  1998cited by this paper
• The area under the plasma concentration–time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin

  1998cited by this paper
• Midazolam: a review of therapeutic uses and toxicity.

  1997cited by this paper
• Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

  1997cited by this paper
• Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism

  1996influential reference
• First‐pass metabolism of midazolam by the human intestine

  1996cited by this paper
• Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.

  1996cited by this paper
• Interaction between grapefruit juice and midazolam in humans

  1995influential reference
• Prolonged sedation due to accumulation of conjugated metabolites of midazolam.

  1995cited by this paper
• Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers

  1992cited by this paper
• Solubility and acid-base behaviour of midazolam in media of different pH, studied by ultraviolet spectrophotometry with multicomponent software.

  1991cited by this paper
• Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

  1989cited by this paper
• Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration.

  1988cited by this paper
• Effect of diffusional barriers on drug and metabolite kinetics.

  1987cited by this paper
• Relationship between plasma concentration and effect of midazolam after oral and intravenous administration.

  1983cited by this paper
• A commentary: methods and assumptions in the kinetic estimation of metabolite formation.

  1983cited by this paper
• Pharmacokinetics and bioavailability of midazolam in man.

  1983influential reference
• Excretion and metabolism of 14C-midazolam in humans following oral dosing.

  1981influential reference
• Drug metabolite kinetics.

  1981influential reference
• Sequential first-pass elimination of a metabolite derived from a precursor

  1979cited by this paper
• Hepatic clearance of drugs. III. Additional experimental evidence supporting the “wellstirred” model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liverin situ preparation

  1977cited by this paper

• Effects of Midazolam and Dexmedetomidine on Cognitive Dysfunction Following Open‐Heart Surgery: A Comprehensive Review

  2025cites this paper
• Research on the content and activity of CYP450 enzymes in human liver

  2025influential citation
• Nutrient environment improves drug metabolic activity in human iPSC-derived hepatocytes and HepG2

  2025cites this paper
• A primary human Gut/Liver microphysiological system to estimate human oral bioavailability

  2025cites this paper
• Distribution and elimination kinetics of midazolam and metabolites after post-resuscitation care: a prospective observational study

  2024cites this paper
• Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies

  2024cites this paper
• Clinical Trial Data-Driven Risk Assessment of Drug–Drug Interactions: A Rapid and Accurate Decision-Making Tool

  2024cites this paper
• Introducing the Dynamic Well-stirred Model for Predicting Hepatic Clearance and Extraction Ratio.

  2024cites this paper
• Development of a pharmacokinetic and pharmacodynamic model for intranasal administration of midazolam in older adults: a single-site two-period crossover study.

  2023cites this paper
• Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism

  2023influential citation
• Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam

  2023cites this paper
• Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo

  2023cites this paper
• Predictive Performance of Next Generation Human Physiologically Based Kinetic (PBK) Models Based on In Vitro and In Silico Input Data

  2022cites this paper
• The effects of hexabromocyclododecane on the transcriptome and hepatic enzyme activity in three human HepaRG-based models.

  2022cites this paper
• Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Exposure to a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Substrate of Cytochrome P450 and Aldehyde Oxidase, Using Chimeric Mice With Humanized Liver

  2022influential citation
• Unravelling the pharmacokinetics of aflatoxin B1: In vitro determination of Michaelis–Menten constants, intrinsic clearance and the metabolic contribution of CYP1A2 and CYP3A4 in pooled human liver microsomes

  2022cites this paper
• Predictive performance of next generation human physiologically based kinetic (PBK) model predictions based on in vitro and in silico input data_suppl1

  2022cites this paper
• Effect of cenobamate on the single‐dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects

  2021cites this paper
• Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis

  2021cites this paper
• Complex Cytochrome P450 Kinetics Due to Multisubstrate Binding and Sequential Metabolism. Part 2. Modeling of Experimental Data

  2021cites this paper
• Complex Cytochrome P450 Kinetics Due to Multisubstrate Binding and Sequential Metabolism. Part 1. Theoretical Considerations

  2021cites this paper
• MetaClass, a Comprehensive Classification System for Predicting the Occurrence of Metabolic Reactions Based on the MetaQSAR Database

  2021cites this paper
• Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics

  2021cites this paper
• CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate

  2021cites this paper
• A fast and simple method for the simultaneous analysis of midazolam, 1-hydroxymidazolam, 4-hydroxymidazolam and 1-hydroxymidazolam glucuronide in human serum, plasma and urine.

  2020cites this paper
• PBPK modeling of CYP3A and P-gp substrates to predict drug–drug interactions in patients undergoing Roux-en-Y gastric bypass surgery

  2020cites this paper
• A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.

  2020cites this paper
• THE EFFECTIVE APPLICATION OF METABOLITE PROFILING IN DRUG DESIGN AND DISCOVERY.

  2020cites this paper
• Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling

  2020cites this paper
• Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs

  2020cites this paper
• Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI

  2019influential citation
• Biotransformation of the Mycotoxin Enniatin B1 by CYP P450 3A4 and Potential for Drug-Drug Interactions

  2019cites this paper
• In Vitro and In Vivo Correlation of Hepatic Fraction of Metabolism by P450 in Dogs.

  2019cites this paper
• Prolonged Anesthetic Recovery after Continuous Infusion of Midazolam in 2 Domestic Cats (Felis catus).

  2019cites this paper
• Prediction of Metabolite‐to‐Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model

  2019cites this paper
• Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio

  2018cites this paper
• Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

  2018cites this paper
• Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.

  2017cites this paper
• HALO- AND SOLVATO-FLUOROCHROMIC POLYMER NANOASSEMBLIES FOR CANCER THERANOSTICS

  2017cites this paper
• Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?

  2016cites this paper
• A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose

  2016cites this paper
• The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine

  2016cites this paper
• Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes

  2016cites this paper